BRENUS PHARMA

At Brenus Pharma, we are building a company with a bold ambition to become a leader in immunotherapies, making patients active participants in their own cancer’s treatment.

Cancer is an evolving target that constantly adapts to escape the immune system and resist to treatment.

Given this high unmet need, we developed a tech-platform generating new therapeutic vaccines against cancer, called STC for ‘Stimulated-Tumor-(ghost)-Cells’. STC mimics, in the laboratory, the relapse conditions of patients' tumor cells to educate their immune systems to be able to anticipate, target and destroy these tumor cells as soon as they appear. In other words, it’s like giving the immune system a clearer map to navigate the fight against cancer and restore its role as body’ sentinel.

Our patented platform uses an in-depth understanding of the cancer’s complexity, validated by innovative proteomic analysis cross-matched with patient’s biopsies’ human databases to offer a new type of precision treatment.